The 22 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 202.40, with a high estimate of 235.00 and a low estimate of 102.96. The median estimate represents a +120.51% increase from the last price of 91.79.
The current consensus among 26 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $1.37
Reporting Date Nov 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.